Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature

医学 胰腺癌 免疫疗法 肿瘤科 腺癌 癌症 内科学 化疗 进行性疾病 癌症研究
作者
Lijie Qiu,Chen Liu,Heping Li
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
被引量:2
标识
DOI:10.1097/cad.0000000000001546
摘要

Pancreatic cancer is a highly malignant tumor, and most patients are diagnosed at an advanced stage. Unfortunately, due to the immunosuppressive tumor microenvironment of pancreatic cancer, the benefits of immunotherapy for patients with advanced pancreatic cancer are still unclear. Here, we present two cases of advanced pancreatic cancer being controlled by immunotherapy, with pathological diagnoses of ductal adenocarcinoma and acinar cell carcinoma, respectively. Next-generation sequencing (NGS) of both patients is high tumor mutation burden (tumor mutation burden—High) and microsatellite stable. The patient with pancreatic ductal adenocarcinoma was diagnosed as a locally advanced disease (stage III). She received irreversible electroporation, used the programmed death receptor-1 (PD-1) inhibitor (pembrolizumab) combined with chemotherapy (S-1), and then used only the PD-1 inhibitor as a maintenance treatment. As a result, the patient’s lesion was significantly reduced, with a partial response time of up to 31 months. The patient with acinar cell carcinoma was diagnosed as a metastatic disease (stage IV), next-generation sequencing revealed mutations in SMAD4 and KMT2D, and two chemotherapy regimens were used unsuccessfully. Then, the combination of chemotherapy with PD-1 (tislelizumab) and vascular endothelial growth factor/vascular endothelial growth factor receptor (anlotinib) inhibitors were used, and the lesions of the patient were significantly reduced, and the progression-free survival after immunotherapy was 19 months. In advanced pancreatic cancer, a prognosis of this magnitude is rare. Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
panzhongjie完成签到,获得积分10
刚刚
刚刚
秋言完成签到,获得积分20
2秒前
周周完成签到,获得积分10
3秒前
吕佳完成签到 ,获得积分10
3秒前
陀思妥耶夫斯基完成签到 ,获得积分10
4秒前
guowei完成签到,获得积分20
5秒前
科研通AI5应助FelixChen采纳,获得100
6秒前
lz完成签到,获得积分10
7秒前
TORCH完成签到 ,获得积分10
7秒前
Elsie Liu完成签到,获得积分10
8秒前
无奈尔曼发布了新的文献求助10
8秒前
斯文败类应助guowei采纳,获得30
9秒前
赘婿应助张姣姣采纳,获得10
10秒前
jenningseastera应助李雅玟采纳,获得10
11秒前
momo完成签到,获得积分10
12秒前
所所应助CHEN采纳,获得10
13秒前
传奇3应助科研通管家采纳,获得10
13秒前
酷波er应助科研通管家采纳,获得10
14秒前
搜集达人应助科研通管家采纳,获得10
14秒前
科研通AI2S应助科研通管家采纳,获得10
14秒前
星辰大海应助科研通管家采纳,获得10
14秒前
14秒前
14秒前
14秒前
14秒前
李爱国应助科研通管家采纳,获得10
14秒前
顾矜应助科研通管家采纳,获得10
14秒前
14秒前
情怀应助科研通管家采纳,获得10
15秒前
斯文败类应助科研通管家采纳,获得10
15秒前
斯文败类应助科研通管家采纳,获得10
15秒前
15秒前
Struggle完成签到 ,获得积分10
15秒前
坚强怀绿完成签到,获得积分10
17秒前
17秒前
17秒前
钧凯关注了科研通微信公众号
17秒前
月月发布了新的文献求助10
18秒前
19秒前
高分求助中
Mass producing individuality 600
Разработка метода ускоренного контроля качества электрохромных устройств 500
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
Epigenetic Drug Discovery 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3823043
求助须知:如何正确求助?哪些是违规求助? 3365601
关于积分的说明 10436063
捐赠科研通 3084614
什么是DOI,文献DOI怎么找? 1696909
邀请新用户注册赠送积分活动 816071
科研通“疑难数据库(出版商)”最低求助积分说明 769389